Brief: Axovant Completes Enrollment Of Low-Dose Cohort In Phase 1/2 Study Of AXO-AAV-GM1, Expands Study

Sio Gene Therapies

08/06/2020 14:39

June 8 (Reuters) - Axovant Gene Therapies Ltd  AXGT.O :
    * AXOVANT COMPLETES ENROLLMENT OF LOW-DOSE COHORT IN PHASE
1/2
STUDY OF AXO-AAV-GM1 AND EXPANDS STUDY TO INCLUDE TYPE I
(INFANTILE ONSET) PATIENTS WITH GM1 GANGLIOSIDOSIS
    * AXOVANT GENE THERAPIES LTD - SIX-MONTH DATA FROM LOW-DOSE
COHORT
OF AXO-AAV-GM1 EXPECTED IN Q4 2020
    * AXOVANT GENE THERAPIES LTD - EXPECT TO INITIATE HIGH-DOSE
COHORT
OF AXO-AAV-GM1 IN 2H 2020

Source text for Eikon:  ID:nGNX4XHNvk 
Further company coverage:  AXGT.O 

 ((Reuters.Briefs@thomsonreuters.com;))